Literature DB >> 28820291

Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer.

John T Isaacs1, W Nathaniel Brennen1, Samuel R Denmeade1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28820291      PMCID： PMC5602292          DOI： 10.1080/15384101.2017.1360645

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.

Authors:  Changmeng Cai; Housheng Hansen He; Sen Chen; Ilsa Coleman; Hongyun Wang; Zi Fang; Shaoyong Chen; Peter S Nelson; X Shirley Liu; Myles Brown; Steven P Balk
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

2.  Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.

Authors:  Michael T Schweizer; Emmanuel S Antonarakis; Hao Wang; A Seun Ajiboye; Avery Spitz; Haiyi Cao; Jun Luo; Michael C Haffner; Srinivasan Yegnasubramanian; Michael A Carducci; Mario A Eisenberger; John T Isaacs; Samuel R Denmeade
Journal:  Sci Transl Med       Date:  2015-01-07       Impact factor: 17.956

3.  Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.

Authors:  Ivan V Litvinov; Donald J Vander Griend; Lizamma Antony; Susan Dalrymple; Angelo M De Marzo; Charles G Drake; John T Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

4.  Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.

Authors:  John T Isaacs; Jason M D'Antonio; Shuangling Chen; Lizamma Antony; Susan P Dalrymple; Georges H Ndikuyeze; Jun Luo; Samuel R Denmeade
Journal:  Prostate       Date:  2012-03-06       Impact factor: 4.104

Review 5.  Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation.

Authors:  Donald J Vander Griend; Ivan V Litvinov; John T Isaacs
Journal:  Cell Cycle       Date:  2007-03-21       Impact factor: 4.534

Review 6.  DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer.

Authors:  Jason M D'Antonio; Donald J Vander Griend; John T Isaacs
Journal:  Endocr Relat Cancer       Date:  2009-02-24       Impact factor: 5.678

7.  Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.

Authors:  Mohammad Hedayati; Michael C Haffner; Jonathan B Coulter; Raju R Raval; Yonggang Zhang; Haoming Zhou; Omar Mian; Emma J Knight; Nina Razavi; Susan Dalrymple; John T Isaacs; Aileen Santos; Russell Hales; William G Nelson; Srinivasan Yegnasubramanian; Theodore L DeWeese
Journal:  Clin Cancer Res       Date:  2016-02-01       Impact factor: 12.531
  7 in total
  5 in total

Review 1.  Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.

Authors:  Andrea K Miyahira; Adam Sharp; Leigh Ellis; Jennifer Jones; Salma Kaochar; H Benjamin Larman; David A Quigley; Huihui Ye; Jonathan W Simons; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2019-12-11       Impact factor: 4.104

Review 2.  Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells?

Authors:  John T Isaacs
Journal:  Am J Clin Exp Urol       Date:  2018-04-01

3.  Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.

Authors:  Michael C Haffner; Akshay Bhamidipati; Harrison K Tsai; David M Esopi; Ajay M Vaghasia; Jin-Yih Low; Radhika A Patel; Gunes Guner; Minh-Tam Pham; Nicole Castagna; Jessica Hicks; Nicolas Wyhs; Ruedi Aebersold; Angelo M De Marzo; William G Nelson; Tiannan Guo; Srinivasan Yegnasubramanian
Journal:  Prostate       Date:  2021-08-16       Impact factor: 4.104

4.  Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question.

Authors:  Irene Caramella; Alberto Dalla Volta; Marco Bergamini; Deborah Cosentini; Francesca Valcamonico; Alfredo Berruti
Journal:  Endocrine       Date:  2022-08-20       Impact factor: 3.925

5.  The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.

Authors:  Kimia Mirzakhani; Julia Kallenbach; Seyed Mohammad Mahdi Rasa; Federico Ribaudo; Martin Ungelenk; Marzieh Ehsani; Wenrong Gong; Nikolaus Gassler; Mirjam Leeder; Marc-Oliver Grimm; Francesco Neri; Aria Baniahmad
Journal:  Oncogene       Date:  2021-10-19       Impact factor: 9.867
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.